Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an important role in advancing these novel treatments to the clinic. With recent agreements, MD Anderson has expanded its manufacturing and research capacity for cell therapies to bring new treatment options to more patients.
This month, MD Anderson finalized an asset purchase agreement with Bellicum...
Researchers from MD Anderson have revealed how glioma cells move and infiltrate the brain, providing a new potential treatment pathway to...
A study published in JAMA comparing adverse event outcomes by treatment type for patients with localized prostate cancer reveals most...
MD Anderson has created a new research platform to drive the discovery of new therapeutic agents for patients with leukemia by investigating the complex interactions and changes between cancer cells and the immune system over time.
ECLIPSE – or Evolution of Cancer, Leukemia, and Immunity Post Stem cEll transplant -- is one of the platforms launched by MD Anderson’s Moon Shots Program® to provide unique expertise...
An immunotherapy used against advanced non-small cell lung
cancer is being tested at MD Anderson for a different...
Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in...
Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic lymphoblastic...
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches...
November is Lung Cancer Awareness Month, and the third Thursday of each November is designated by the American Cancer Society as the Great...
Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type...